New Carocell Bio corporate video
We’re pleased to share a new corporate video of our CEO Mike Davies. In the video, he discusses Carocell Bio, its technology, and how it could improve patients’ lives with its anti-inflammatory peptides applied topically to the skin. Carocell Bio’s anti-inflammatory approach not only has the potential to treat and prevent the recurrence of eczema (atopic […]
<strong>Carocell Bio reveals positive new preclinical data from patient biopsies</strong>
Cheadle, UK – 10 January 2022 – Today, Carocell Bio, the anti-inflammation therapeutics company, announced that its lead anti-inflammatory peptide JEL0305 shows efficacy in human inflammatory disease tissue biopsies. The candidate peptide-based treatment provides an innovative approach to treat atopic dermatitis (eczema, AD), prevent it’s recurrence and possibly delay ageing of the skin through a […]
<strong>Carocell Bio announces further $500k fundraise to pursue preclinical anti-inflammatory skin studies</strong>
Greater Manchester, UK – 14 Dec 2022 – Today, Carocell Bio, the anti-inflammation therapeutics company, announced that it has received USD $500,000 (£404,000) in further funding from Deepbridge Capital, an investment firm focused on life sciences, disruptive technologies and renewable energy. The funds will support pivotal pre-clinical testing data for Carocell Bio’s lead anti-inflammatory peptide […]
Carocell Bio Presenting at BIO 2022
GREATER MANCHESTER, UK – 13 June 2022 – Carocell Bio, the anti-inflammation company revolutionising the treatment of inflammatory diseases with its peptide-based approach to mitogen-activated protein kinase inhibitors (MAPKi), has announced that its CEO, Mike Davies, who is attending the BIO 2022 International Convention, will be presenting today, Monday 13 June, at 12.30 pm PDT […]
Carocell Bio Selected as Finalist for RESI Innovator’s Pitch Challenge
GREATER MANCHESTER, UK – 6 June 2022 – Today, Carocell Bio, the anti-inflammation company revolutionising the treatment of inflammatory diseases with its peptide-based approach to mitogen-activated protein kinase inhibition (MAPKi), announced that it had been selected to pitch to investors at the Redefining Early Stage Investments (RESI) Digital Innovator’s Pitch Challenge. The pitching event, taking place […]
Carocell Bio receives ethical approval for human pre-clinical testing of lead proprietary peptide in collaboration with Oxford clinical researcher
Testing anti-inflammation approach to treat burns and scarring is key step in therapeutic development and potential progression to clinical testing GREATER MANCHESTER, UK – 17 May 2022 – Today, Carocell Bio has announced that it has received approval from the Health Research Authority (HRA) to test its lead candidate proprietary peptide JEL3108 in human burns […]
Leading the industry with a unique anti-inflammation approach to scarring
Interview with Dr Mike Davies, Founder and CEO, Carocell Bio In this Q&A Dr Davies reflects on his career to-date, including his background in surgery and the pharmaceutical and biotech industry, as well as the exciting challenge Carocell Bio is addressing with its anti-inflammation approach to scarring. Can you tell me a bit about your […]
Carocell Bio to Present at CONNECTpreneur Investor Network Event
GREATER MANCHESTER, UK – Carocell Bio, the UK- and US-based company focused on the development of anti-inflammatory therapeutics, announced that today, Thursday, 24 February 2022, its CEO Dr Mike Davies, will present at Rocket Pitch + Power Networking, a CONNECTpreneur Investor Network Virtual Event, between 4-6 pm GMT. Described as one of the world’s largest […]
Carocell Bio to Speak at 2022 BIO CEO and Investor Conference
GREATER MANCHESTER, UK – Carocell Bio, the UK-based company focused on the development of anti-inflammatory therapeutics, is pleased to announce that its CEO, Dr Mike Davies, will be speaking at the 2022 BIO CEO and Investor Conference, being held 14-17 February 2022 in New York, USA. Dr Davies will present on Carocell Bio, including details […]
Carocell Bio secures close to £100,000 in additional funding from Innovate UK
GREATER MANCHESTER, UK – Today Carocell Bio, the anti-inflammation therapeutics company, announced that it has been awarded additional funding from Innovate UK. The grant aims to support the company’s research into novel peptides and nanoparticle technology with the goal of preventing scar formation after surgery, and mitigating the challenges of 2nd and 3rd degree burns […]
Carocell Bio secures additional investment from Deepbridge Capital following successful pre-clinical study
GREATER MANCHESTER, UK – Today, Carocell Bio, the UK-based anti-inflammation therapeutics company, is pleased to announce a further £150,000 in funding from Deepbridge Capital. The investment follows successful pre-clinical studies with the company’s JEL3108 lead anti-inflammatory peptide. JEL3108 provides a potential first-line treatment for scar prevention and the treatment of burns, including the reduction of […]
Carocell Bio gains Innovate UK Smart grant to progress anti-inflammatory burns treatment
GREATER MANCHESTER, UK – Today, Carocell Bio, the UK-based anti-inflammation therapeutics company, has been awarded an Innovate UK Smart grant of over £270,000 for the development of its lead JEL3108 peptide for burns treatment. JEL3108 has the potential to reduce burn pain and aid in scar prevention. The funding will help support further formulation development […]
Carocell Bio welcomes £250,000 investment from Deepbridge Capital
GREATER MANCHESTER, UK – Today, Carocell Bio, the anti-inflammation therapeutics company, announced that it has received £250,023.32 from Deepbridge Capital, an investment firm focused on life sciences, disruptive technologies and renewable energy. The news follows initial pre-clinical testing data for Carocell Bio’s lead anti-inflammatory peptide JEL3108, which provides an innovative approach to preventing scar formation […]
BioSeed 2020
BioSeed 2020, London – January 20, 2020 GREATER MANCHESTER, UK – Carocell Bio will be presenting at BioSeed 2020, we look forward to seeing you there.
J.P. Morgan Healthcare Conference
38th J.P. Morgan Healthcare Conference, San FranciscoJanuary 13-16, 2020 GREATER MANCHESTER, UK – Carocell Bio will be attending the 38th J.P Morgan Healthcare Conference on January 13-16, 2020.
BioEurope 2019
BioEurope 2019, Hamburg – Nov 11-13, 2019 GREATER MANCHESTER, UK – Dr Mike Davies will be present and available for meetings. We very much look forward to seeing you in Hamburg.
Investival Showcase 2019
Inv€$tival Showcase 2019, London – Nov 19, 2019 GREATER MANCHESTER, UK – Carocell Bio will be attending the conference and available for meet anyone interested in our research and investment opportunities.
Carocell Bio is the new name for Bridge Biotec
GREATER MANCHESTER, UK – Today, Carocell Bio is pleased to announce that it recently changed its company name, from Bridge Biotec. The company looks forward to updating you soon with research news and investment opportunities.
BIO International Convention – June 3-6, 2019
GREATER MANCHESTER, UK – Bridge Biotec will be attending this event in Philadelphia, PA